Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas.
Saved in:
| Title: | Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. |
|---|---|
| Authors: | O'Sullivan Coyne G; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA., Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA., Rubinstein LV; Biometric Research Program, NCI, NIH, Bethesda, MD, USA., Wilsker D; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Moore N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA., Hogu M; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA., Piekarz R; Cancer Therapeutics Evaluation Program, NCI, NIH, Bethesda, MD, USA., Covey J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA., Beumer JH; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Ferry-Galow KV; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Villaruz LC; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Hollingshead MG; Biological Testing Branch, NCI, NIH, Frederick, MD, USA., Holleran JL; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Deppas JJ; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Pommier Y; Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA., Ko B; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA., Johnson BC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA., Parchhment RE; Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Ivy P; Cancer Therapeutics Evaluation Program, NCI, NIH, Bethesda, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.; Center for Cancer Research, NCI, NIH, Bethesda, MD, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA. chenali@mail.nih.gov. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2025 May 29; Vol. 95 (1), pp. 58. Date of Electronic Publication: 2025 May 29. |
| Publication Type: | Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
